Email this article 
Post a Comment Risk factors for development of type 2 diabetes mellitus in patients with obesity in late post-COVID period
- Authors: Yuzhakova E.V.1, Shanko Z.G.1, Smirnova E.N.1
-
Affiliations:
- E.A. Vagner Perm State Medical University
- Issue: Vol 41, No 1 (2024)
- Pages: 81-89
- Section: Original studies
- URL: https://journals.rcsi.science/PMJ/article/view/254847
- DOI: https://doi.org/10.17816/pmj41181-89
- ID: 254847
Cite item
Full Text
Abstract
Objective. To study the risk factors for developing type 2 diabetes mellitus in patients with obesity after COVID-19.
Materials and methods. 61 case histories and outpatient card abstracts of patients with obesity, who suffered from moderate and severe forms of COVID-19 from 02.2021–04.2022 were analyzed. Demographic, laboratory and clinical parameters were studied during hospitalization and 12 months after discharge from the hospital. All patients initially were divided into 2 groups according to the glycated hemoglobin level. Group 1 consisted of 46 patients with prediabetes and group 2 included 15 patients without carbohydrate disorders.
Results. The median age of all patients was 64 (59–66) years. Median of HbAlc was 6,0 (5,6–6,2) %, BMI –34 (33–35) kg/m2. 24 patients from group 1, who took DPP-4-inhibitors in early post-COVID-19 period constituted subgroup 1A and 22 patients, who refused treatment with these drugs, constituted subgroup 1B. Currently, 2 patients from subgroup 1A and 10 patients from subgroup 1B (χ2=8,2 р=0,004) have been diagnosed with DM2. In patients who developed DM2 in late post-COVID period the levels of HbAlc, fasting plasms glucose and BMI at the time of admission to the hospital were significantly higher (n=12) than in patients with persistent prediabetes (n=34), (p<0,05). Positive correlation between these parameters and the risk of developing DM2 (R=0,5, p<0,05; R=0,74, p<0,05; R=0,54, p<0,05, respectively) was determined. In group 2, DM2 is currently diagnosed in 2 male patients with BMI over 40 kg/m2. When comparing subgroup 1B and group 2, it was found out that DM2 in the post-COVID period occurs in every second patient with the previous initial carbohydrate disorders: in 10 people of 22 – in subgroup 1B (every 2nd patient) versus 2 patients from group 2 (every 7th patient), (χ2=4,2, p=0,04). Online calculator from medstatistic. ru was used to determine relative risk (RR).
Conclusions. Thus, presence of impaired glucose tolerance increases the risk of development of DM2 in late post-COVID period. In patients with hyperlycemia on hospitalization for COVID-19, who did not receive incretin therapy (subgroup 1B) risk of DM2 was 3,4 times higher (CI 95 %=0,87–13,40). Patients, who received incretin (subgroup 1A) had risk of DM2 = 0,6 (CI 95 %=0,09–3,97). It should be assumed that incretin therapy prevents development of DM2 in patients with hyperglycemia/impaired glucose tolerance after COVID-19.
Full Text
##article.viewOnOriginalSite##About the authors
E. V. Yuzhakova
E.A. Vagner Perm State Medical University
Author for correspondence.
Email: uzkaty@mail.ru
ORCID iD: 0000-0001-5262-9378
Candidate of Medical Sciences, Associate Professor of the Department of Endocrinology and Clinical Pharmacology
Russian Federation, PermZ. G. Shanko
E.A. Vagner Perm State Medical University
Email: uzkaty@mail.ru
ORCID iD: 0009-0003-7873-0505
Candidate of Medical Sciences, Assistant of the Department of Endocrinology and Clinical Pharmacology
Russian Federation, PermE. N. Smirnova
E.A. Vagner Perm State Medical University
Email: uzkaty@mail.ru
ORCID iD: 0000-0003-2727-5226
MD, PhD, Professor, Head of the Department of Endocrinology and Clinical Pharmacology
Russian Federation, PermReferences
- Petrilli C.M., Jones S.A., Yang J., Rajagopalan H., O'Donell L., Chernyak Y., Tobin K.A., Cerfolio R.J., Francois F., Horwitz L.I. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. medRxiv. January 2020: 2020.04.08.20057794. doi: 10.1101/2020.04.08.20057794
- Simonnet A, Chetboun M, Poissy J., Ravrdy V., Noulette J., Duhamel A., Labreuche J., Mathieu D., Pattou F., Jourdain M. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. Obesity. 2020; 28 (7): 1195–1199. doi: 10.1002/oby.22831
- Cai Q, Chen F. Wang T., Luo F., Liu X., Wu Q., He Q., Wang Z., Liu Z., Liu Y., Liu L., Chen J., Xu L. Obecity and COVID-19 severity in a designated hospital in Shenzhen, China. Diabetes Care. 2020: 43 (7): 1392–8. doi: 10.2337/dc20-0576
- Фурсов А.Б., Останов О.Б., Фурсов Р.А. Ожирение и COVID-19 – признаки конвергенции двух пандемий. Рекомендации по борьбе с ожирением, основанных на принципах “ROOTS”. Ожирение и метаболизм 2021; 18 (4): 456–464. doi: 10.14341/omet12745 / Fursov A.B., Ostanov O.B., Fursov R.A. Obesity and COVID-19 are signs of the convergence of two pandemics. Recommendations for combating obesity based on the principles of “ROOTS”. Ozhirenie i metabolizm 2021; 18 (4): 456–464. doi: 10.14341/omet12745 (in Russian).
- Huang C, Wang Y, Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., XiaoY., Gao H., Guo L., Xie J.,Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. Lancet. 2020; 395 (10223): 497–506. DOI: 10.101/S0140-6736(20)30183-5.
- Демидова Т.Ю., Волкова Е.И., Грицкевич Е.Ю. Особенности течения и последствия COVID-19 у пациентов с избыточным весом и ожирением. Уроки текущей пандемии. Ожирение и метаболизм 2020: 17 (4): 375–384. doi: 10.14341/omet12663 / Demidova T.Ju., Volkova E.I., Grickevich E.Ju. Features of the course and consequences of COVID-19 in overweight and obese patients. Lessons from the current pandemic. Ozhirenie i metabolizm 2020; 17 (4): 375–384. doi: 10.14341/omet12663 (in Russian).
- Салухов В.В., Арутюнов Г.П., Тарловская Е.И., Батлук Т.И., Башкинов Р.А., Самусь И.В., Мельников Е.С., Трубникова М.А., Арутюнов А.Г. Влияние нарушений углеводного обмена на ранние и отдаленные клинические исходы у пациентов с COVID-19 по данным регистров АКТИВ и АКТИВ2. Проблемы эндокринологии 2023; 69 (1): 36–49. doi: 10.14341/probl13175 / Saluhov V.V., Arutjunov G.P., Tarlovskaja E.I., Batluk T.I., Bashkinov R.A., Samus' I.V., Mel'nikov E.S., Trubnikova M.A., Arutjunov A.G. The impact of carbohydrate metabolism disorders on early and long-term clinical outcomes in patients with COVID-19 according to the ACTIV and ACTIV2 registers. Problemy jendokrinologii 2023; 69 (1): 36–49. doi: 10.14341/probl13175 (in Russian).
- Шаталова О.В., Глазова Г.М., Пономарева А.В. Синдром гипергликемии при новой коронавирусной инфекции. Лекарственный вестник 2022; 23 (1): 18–21/Shatalova O.V., Glazova G.M., Ponomareva A.V. Hyperglycemia syndrome during new coronavirus infection. Lekarstvennyj vestnik 2022; 23 (1): 18–21 (in Russian).
- Игнатенко Г.А., Багрий А.Э., Приколота О.А., Приколота А.В., Могилевская К.Э. Сахароснижающая терапия и течение постковидного синдрома, есть ли связь? Архив внутренней медицины 2023; 13 (2): 129–135. doi: 10.20514/2226-6704-2023-13-2-129-135 / Ignatenko G.A., Bagrij A.Je., Prikolota O.A., Prikolota A.V., Mogilevskaja K.Je. Antihyperglycemic therapy and the course of post-Covid syndrome, is there a connection? Arhiv vnutrennej mediciny 2023; 13 (2): 129–135. doi: 10.20514/2226-6704-2023-13-2-129-135 (in Russian).
- Мартынов А.И., Маляев А.Г., Демидова Т.Ю., Мкртумян А.М. Поражение эндокринной системы при Long-COVID-инфекции. Терапия 2022; 1: 1–147. doi: 10.18565/therapy.2022.1suppl.1-147 / Martynov A.I., Maljaev A.G., Demidova T.Ju., Mkrtumjan A.M. Damage to the endocrine system during Long-COVID infection. Therapy 2022; 1: 1–147. doi: 10.18565/therapy.2022.1suppl.1-147 (in Russian).
- Ayoubkhani D., Khunti K., Maddox T.N., Humberstone B., Diamond S.I. Epidemiology of post-COVID syndrome following hospitalization with coronavirus: A retrospective cohort study. medRxiv. 2021. doi: 10.1101/2021.01.15.21249885
- Гуревич К.Г., Сорокина Ю.А., Ураков А.Л., Синюшкина С.Д., Пряжников М.И., Горинова А.В., Ловцова Л.В., Занозина О.В. Иммунотропные эффекты сахароснижающих средств на фоне коронавирусной инфекции: взгляд с позиции фармакогенетики. Обзоры по клинической фармакологии и лекарственной терапии 2022; 20 (3): 269–279 / Gurevich K.G., Sorokina Ju.A., Urakov AL., Sinjushkina S.D., Prjazhnikov M.I., Gorinova A.V., Lovcova L.V., Zanozina O.V. Immunotropic effects of hypoglycemic druga against the background of coronavirus infection: a view from the perspective of pharmacogenetics. Obzory po klinicheskoj farmakologii i lekarstvennoj terapii 2022; 20 (3): 269–279 (in Russian).
- Li Y., Zhang Z., Yang L., Lian X., Xie Y., Li S., Xin S., Cao P., Lu J. The MERS-CoV receptor DPP4 as a candidate binding target of the SARS-CoV-2 spike. iScience. 2020; 23 (8): 101400. doi: 10.1186/s13098-021-00639-2
- Solerte S.B., D’addio F., Trevisan R., Lovatti I., Rossi A., Pastore I. Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study Diabetes Care. 2020 Dec; 43 (12): 2999–3006. doi: 10.2337/dc20-1521
- Al-Kuraishy H.M., Al-Gareeb A.I., Qusty N., Alexiou A., Batith G.I-S. Impact of Sitagliptin on Non-diabetic Covid-19 Patients. Curr Mol Pharmacol. 2022; 15 (4): 683–692. doi: 10.2174/1874467214666210902115650
- Сорокина Ю.А., Суханов С.А., Николаева А.А. Сахароснижающая терапия у больных сахарным диабетом 2-го типа и COVID-19. Эффективная фармакотерапия 2022; 18 (6): 10–19. doi: 10.33978/2307-3586-2022-18-6-10-19 / Sorokina Ju.A., Suhanov S.A., Nikolaeva A.A Antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19. Jeffektivnaja farmakoterapija 2022; 18 (6): 10–19 doi: 10.33978/2307-3586-2022-18-6-10-19 (in Russian).
Supplementary files
